⌘K

/

/

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

Models
Drugs
Insights

Company

CRO Partners
Contact Us
Privacy Policy

© 2025 Fibrosis-Inflammation Lab. All rights reserved.

Privacy Policy Terms of Service

Orforglipron (Orforglipron) | Accelerate Your Fibrosis Research

Home/Drugs/Orforglipron

Orforglipron

Orforglipron

Phase 3

Sponsor: Eli Lilly

Indication: Obesity / MASH

Mechanism of Action

Oral GLP-1 Agonist

Target: GLP-1

Clinical Information

Approval Year

Clinical Trials (ClinicalTrials.gov)

COMPLETEDNCT05469126

A Drug Interaction Study of Clarithromycin and LY3502970 in Healthy Participants

Phase:PHASE1Org:Eli Lilly and Company

COMPLETED

Relevant Publications (PubMed)

Orforglipron: A Novel Oral GLP-1 Agonist for the Treatment of Obesity and Diabetes.

Pillai AA, Sharma AM, Krayem H et al.

Cardiol Rev2025 Dec 16

Medical Management of Obesity: A Comprehensive Review of Food and Drug Administration (FDA)-Approved and Investigational Therapies.

Raza SS, Zakir Z, Hashmat A et al.

Cureus2025 Nov

The Obesity Drug Revolution: New Frontiers in Pharmacotherapy.

Manoria PC

Cureus2025 Nov

One small molecule for man, one giant leap for mankind with obesity.

Novikoff A, Müller TD

Validated Models

This drug has been validated in the following preclinical models:

NCT05971940

A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone

Phase:PHASE3Org:Eli Lilly and Company

RECRUITINGNCT07153471

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

Phase:PHASE3Org:Eli Lilly and Company

ACTIVE_NOT_RECRUITINGNCT06649045

A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Phase:PHASE3Org:Eli Lilly and Company

COMPLETEDNCT05051579

A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities

Phase:PHASE2Org:Eli Lilly and Company

View all trials on ClinicalTrials.gov

Med2025 Dec 12

Orforglipron, quand le GLP-1 devient simple et oral.

Comte D

Rev Med Suisse2025 Dec 3

View more on PubMed